BRAF and neoplasm: It is recommended to conduct targeted tests during or after first-line treatment in order to identify specific molecular abnormalities such as tumours with isocitrate dehydrogenase-1 (IDH-1) mutations, fibroblast growth factor receptor-2 (FGFR-2) fusions, human epidermal growth factor-2 (HER-2) amplifications, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, MDM2 amplifications, and/or microsatellite instability.